Global Coalition Against Pneumonia

Global Coalition for Adaptive Research in Collaboration with Cure Brain Cancer Foundation Announce the Opening of Glioblastoma Clinical Trial in Australia

Retrieved on: 
Tuesday, November 14, 2023
Science, Research, Pharmaceutical, Oncology, Health, Philanthropy, Clinical Trials, Foundation, AGILE, Radiation, Hope, Glioblastoma, GBM, Patient, Multimedia, Royal North Shore Hospital, Survival, Hospital, Global Coalition Against Pneumonia, Brain, Medical imaging, Pharmaceutical industry

The Global Coalition for Adaptive Research (GCAR) in collaboration with Cure Brain Cancer Foundation (CBCF), today announced the opening of GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment – NCT03970447) in Australia.

Key Points: 
  • The Global Coalition for Adaptive Research (GCAR) in collaboration with Cure Brain Cancer Foundation (CBCF), today announced the opening of GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment – NCT03970447) in Australia.
  • GBM AGILE is a revolutionary patient-centered, adaptive platform trial for registration that evaluates multiple therapies for patients with newly-diagnosed and recurrent glioblastoma (GBM) – the deadliest form of brain cancer.
  • “Cure Brain Cancer Foundation is an organization dedicated to rapidly improving brain cancer survival and ultimately finding a cure.
  • We are thrilled that patients in Australia will be able to participate in this innovative clinical trial,” said Lance Kawaguchi, CEO, Cure Brain Cancer Foundation.

Global Platform Study Presents Results to Guide Care of Severely Ill Patients With COVID-19 Using Routinely Available Drugs – Simvastatin and Vitamin C

Retrieved on: 
Wednesday, October 25, 2023
Science, Research, Pharmaceutical, Health, COVID-19, Infectious Diseases, Hospitals, Clinical Trials, WHO, Urinary tract infection, Survival, FRCP, Patient, Vitamin C, Simvastatin, Royal Victoria Hospital, Montreal, Bronchopneumonia, MPH, Global Coalition Against Pneumonia, Oregon Health & Science University, University, Respiratory tract infection, JAMA, Professor, Vitamin, Multimedia, Queen's University Belfast, University of Pittsburgh School of Medicine, Learning, Critical Care Medicine (journal), COVID, Clinical trial, Intensive care unit, Hospital, NEJM, Probability, Pittsburgh, European Society of Clinical Microbiology and Infectious Diseases, Wilfrid Sellars, SUNY Downstate Health Sciences University, Hospice and palliative medicine, Intensive care medicine, Royal Victoria Hospital, UPMC, Consultant, Ohio State University Wexner Medical Center, Pharmaceutical industry, Dietary supplement, MD

Vitamin C is widely available around the world and was used in some settings for the treatment of COVID-19.

Key Points: 
  • Vitamin C is widely available around the world and was used in some settings for the treatment of COVID-19.
  • Through harmonizing two clinical trials – REMAP-CAP and LOVIT-COVID – over 2500 patients in 20 countries took part, including both critically ill and non-critically ill patients with COVID-19 in hospital.
  • It was shown that high dose vitamin C did not improve outcomes for patients.
  • Intravenous Vitamin C for Patients Hospitalized with COVID-19: Two Harmonized Randomized Clinical Trials.

Children's Tumor Foundation and Global Coalition for Adaptive Research Announce Strategic Alliance to Implement NF Platform Clinical Trial

Retrieved on: 
Thursday, October 5, 2023
Neurofibromatosis, Partnership, Global Coalition Against Pneumonia, COVID-19, Learning, Biomarker, Research, GBM, Organization, IMI, Cancer, Schwannomatosis, Neurofibroma, NF, Patient, Paratriathlon, Children's Tumor Foundation, Deafness, Clinical trial, NF1, IHI, CTF, DSM-IV codes, Neoplasm, Glioblastoma, Library, Glioma, EU, Innovative Medicines Initiative, Pharmaceutical industry, SWN

NEW YORK, Oct. 5, 2023 /PRNewswire/ -- The Children's Tumor Foundation (NEW YORK, NY and BRUSSELS, BELGIUM) and the Global Coalition for Adaptive Research (LARKSPUR, CA) – The Children's Tumor Foundation (CTF) and Global Coalition for Adaptive Research (GCAR), today announced their alliance to accelerate the development of treatments for patients with NF (neurofibromatosis or schwannomatosis) – a group of rare and often debilitating diseases with high unmet medical need. CTF and GCAR are partnering to operationalize a first-of-its-kind clinical trial for patients with NF that was initially designed through the EU-PEARL initiative.

Key Points: 
  • CTF and GCAR are partnering to operationalize a first-of-its-kind clinical trial for patients with NF that was initially designed through the EU-PEARL initiative.
  • The establishment of the NF platform trials will expedite the development of effective treatments for patients," said Dr. Annette Bakker, President of the Children's Tumor Foundation.
  • Our alliance with CTF exemplifies a collaboration that places patients and the community at the forefront of clinical research."
  • Additionally, the Foundation's NF Patient Registry provides dependable access to NF patients available to participate in NF clinical trials and research studies.

Government of Canada joins the Global Coalition on Telecommunications

Retrieved on: 
Thursday, October 5, 2023
Global Coalition Against Pneumonia, Government, United Kingdom, Government of Canada, The Honourable, Policy, Mobile phone, Telecommunications, Science

TORONTO, Oct. 5, 2023 /CNW/ - Ensuring that telecommunications networks are secure, resilient and innovation-focused is a global priority.

Key Points: 
  • TORONTO, Oct. 5, 2023 /CNW/ - Ensuring that telecommunications networks are secure, resilient and innovation-focused is a global priority.
  • That's why the Government of Canada is working with international partners to ensure Canadians have access to secure and reliable telecom services.
  • Today, the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, announced Canada has joined the United Kingdom, the United States, Australia and Japan in launching the Global Coalition on Telecommunications (GCOT).
  • This initiative seeks to build a coalition of countries and stakeholders to foster diverse supply chains, secure and interoperable standards, and innovation in the telecommunications sector.

Global Coalition for Adaptive Research and Polaris Group Announce Commencement of ADI-PEG 20 in GBM AGILE Trial

Retrieved on: 
Tuesday, August 15, 2023
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Pancreatic cancer, Learning, Yale School of Medicine, University, Polaris, GBM, Neurology, Hepatocellular carcinoma, Neuro-Oncology (journal), MGMT, Coalition, Survival, Arginine, NDA, Yale school, Multimedia, Cell, Lung cancer, Brain, Associate, Glioblastoma, Global Coalition Against Pneumonia, Assistant, Acute myeloid leukemia, Patient, Melanoma, SAN, Cancer, Mesothelioma, FDA, BLA, Pharmaceutical industry, Medical imaging, Medicine

Global Coalition for Adaptive Research (LARKSPUR, CA) and Polaris Pharmaceuticals, Inc. (SAN DIEGO, CA), a subsidiary of Polaris Group (TWSE:6550)— The Global Coalition for Adaptive Research (GCAR) in collaboration with Polaris, today announced the activation of ADI-PEG 20 in GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment – NCT03970447).

Key Points: 
  • Global Coalition for Adaptive Research (LARKSPUR, CA) and Polaris Pharmaceuticals, Inc. (SAN DIEGO, CA), a subsidiary of Polaris Group (TWSE:6550)— The Global Coalition for Adaptive Research (GCAR) in collaboration with Polaris, today announced the activation of ADI-PEG 20 in GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment – NCT03970447).
  • GBM AGILE is a revolutionary patient-centered, adaptive platform trial for registration that evaluates multiple therapies for patients with newly-diagnosed and recurrent glioblastoma (GBM) – the deadliest form of brain cancer.
  • View the full release here: https://www.businesswire.com/news/home/20230815912018/en/
    Polaris’ ADI-PEG 20 is entering the GBM AGILE trial, which initially opened in July 2019 and has screened over 1,500 patients to date.
  • The ADI-PEG 20 arm of GBM AGILE will be enrolling patients with newly-diagnosed unmethylated MGMT, newly-diagnosed methylated MGMT, and recurrent GBM.

HSS Achieves Record 14th Consecutive National No. 1 Ranking in Orthopedics by U.S. News & World Report

Retrieved on: 
Tuesday, August 1, 2023
American Hospital Association, Human, Osteoarthritis, Psoriatic arthritis, US Youth Soccer National Championships, Evidence-based medicine, Centers for Medicare & Medicaid Services, Elective surgery, Culture, National Basketball Players Association, Hospital, Infection, Nursing, Scleroderma, MBA, Pickleball, Research, Lupus, American Animal Hospital Association, Doctor of Philosophy, Neck, The Internationale, Rheumatoid arthritis, Brooklyn Nets, Global Coalition Against Pneumonia, Pain, Medicare, Hospital for Special Surgery, Team physician, MD, Patient, Division, Medical Center, HSS, Joint, Health, New York Red Bulls, News, Safety, New York Road Runners, Health care, Rheumatology, U.S. News & World Report, New York Mets

NEW YORK, Aug. 1, 2023 /PRNewswire/ -- Hospital for Special Surgery (HSS), has been ranked the No. 1 hospital in the nation for orthopedics for the 14th consecutive year, and advanced to No. 2 for rheumatology, in the U.S. News & World Report 2023-2024 Best Hospitals: Specialty Rankings©* analysis. 

Key Points: 
  • 1 hospital in the nation for orthopedics for the 14th consecutive year, and advanced to No.
  • 2 for rheumatology, in the U.S. News & World Report 2023-2024 Best Hospitals: Specialty Rankings©* analysis.
  • HSS maintains the lowest readmission rates for orthopedics in the nation, and among the lowest rates for infections and complications.
  • * Copyright © 2023 U.S. News & World Report, L.P. Data reprinted with permission from U.S. News.

Kintara Therapeutics to Participate in the Fifth Annual Glioblastoma Awareness Day in Washington, D.C.

Retrieved on: 
Wednesday, July 19, 2023
Senate, GBM, New Drug Application, NDA, Research, Global Coalition Against Pneumonia, Patient, Physician, SAN, FDA, Therapy, Pharmaceutical industry, Glioblastoma

SAN DIEGO, July 19, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced its participation in the fifth annual Glioblastoma Awareness Day, July 19, 2023 in Washington, D.C.

Key Points: 
  • SAN DIEGO, July 19, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced its participation in the fifth annual Glioblastoma Awareness Day, July 19, 2023 in Washington, D.C.
  • Originally introduced to the Senate by a bipartisan group of U.S. senators, the inaugural Glioblastoma Awareness Day took place on July 17, 2019.
  • "We are honored to participate in the Glioblastoma (GBM) Awareness Day and to be joined by patients, advocates, physicians, and politicians to continue to raise awareness for GBM research and advancement," said Robert E. Hoffman, the President and CEO of Kintara Therapeutics.
  • A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma - Full Text View - ClinicalTrials.gov

KAZIA CEO, DR. JOHN FRIEND TO PARTICIPATE IN WHITE HOUSE CANCER MOONSHOT

Retrieved on: 
Thursday, May 25, 2023
White House, Disease, Radiation, Society, Drug development, GBM, Neuro-Oncology (journal), ONC201, Survival, American Association for Cancer Research, Research, Brain, Melanoma, Global Coalition Against Pneumonia, White, II, KZIA, DIPG, Patient, Cancer, Cancer Moonshot, Diagnosis, Diffuse intrinsic pontine glioma, PNOC, Oncology, FDA, Melanoma Research, Caregiver, Medical imaging, Glioblastoma, Kazia Pelka

SYDNEY, May 25, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, has been invited to the White House to participate in the Cancer Moonshot Brain Cancers Forum on Glioblastoma (GBM) & Diffuse Intrinsic Pontine Glioma (DIPG), to be held on Thursday, 25 May 2023. 

Key Points: 
  • Kazia's CEO, Dr. John Friend, was invited and will be participating in this forum.
  • Friend to participate in the forum reflects the importance of Kazia's work in developing treatments for GBM and DIPG and reconfirms Kazia's position as a global leader in this field.
  • "We are honored to participate in the Cancer Moonshot forum on adult and pediatric brain cancer alongside global Neuro-Oncology thought leaders, researchers, US government officials and patient advocates," stated Dr.
  • GBM is the most aggressive and most common primary brain cancer with a five-year survival rate of approximately 10%.

Kintara Therapeutics to Commemorate National Brain Tumor Awareness Month with Ringing the Bell at Nasdaq Closing Along with Global Coalition for Adaptive Research and the National Brain Tumor Society

Retrieved on: 
Friday, May 19, 2023
Therapy, GBM, National Brain Tumor Society, Cancer, Research, Brain, Global Coalition Against Pneumonia, Organization, Patient, SAN, Pharmaceutical industry

The event will serve as a commemoration of National Brain Tumor Awareness Month (#GoGrayinMay), an important initiative dedicated to raising awareness and advancing research in the fight against brain cancer.

Key Points: 
  • The event will serve as a commemoration of National Brain Tumor Awareness Month (#GoGrayinMay), an important initiative dedicated to raising awareness and advancing research in the fight against brain cancer.
  • Joining forces with the Global Coalition for Adaptive Research, the influential National Brain Tumor Society, other GBM AGILE Study partners, and patients, Kintara Therapeutics aims to highlight the collective efforts and breakthroughs in cancer treatment and research.
  • By ringing the Nasdaq Closing Bell, the event will symbolize the dedication and ongoing commitment of these organizations to combatting brain cancer on a global scale.
  • "We are honored to participate in the Nasdaq Closing Ceremony and ring the bell alongside the Global Coalition for Adaptive Research, the National Brain Tumor Society, and other GBM AGILE Study collaborators," said Robert E. Hoffman, the President and CEO of Kintara Therapeutics.

Global Heart Hub and the Global Coalition on Aging launch a Global Position Paper on Heart Valve Disease (HVD) and the Healthy Aging Agenda

Retrieved on: 
Thursday, March 23, 2023
Partnership, UN Decade on Ecosystem Restoration, Prevalence, GCOA, HVD, Health, Policy, Global Coalition Against Pneumonia, Patient engagement in Canada, Organization, Incidence, Patient, Diagnosis, Society, Behavior, GHH, Disease, Medical device, Pharmaceutical industry, Ageing

"The impacts of HVD are all the more tragic because they are largely avoidable," said Michael Hodin, CEO of the GCOA.

Key Points: 
  • "The impacts of HVD are all the more tragic because they are largely avoidable," said Michael Hodin, CEO of the GCOA.
  • "The prevalence and incidence is growing apace with the aging of our society.
  • As population aging accelerates, HVD is growing as a life-threatening health challenge and a costly drain on health systems and public budgets.
  • "This should be a true partnership, empowering people to understand the disease, their treatment options, and long-term care plans."